Further subgroup analysis in patients with acral melanoma by PD-L1 expression and BRAF mutation status within the current analysis showed particularly good response and prolonged survival in patients with PD-L1–positive and BRAF wild-type disease. The gene discussed is BRAF; the disease is acral lentiginous melanoma.